Butterfly Network reported preliminary, unaudited revenue growth of at least 17 percent year over year for the quarter ended December 31, 2025. This marks the third consecutive quarter of high-teens revenue increases driven by the company’s handheld ultrasound business. CEO Joseph DeVivo highlighted strong momentum entering 2026, attributing it to the rapid adoption of the iQ3 system, which won Best Medical Technology at the 2024 Prix Galien USA Awards. The company expects to deliver audited fourth quarter and full year results in late February, when it will also issue 2026 guidance, and will present an updated strategic roadmap at the J.P. Morgan Healthcare Conference on January 15.

On January 7, Butterfly’s Executive Vice President and CFO, John Doherty, sold 60,182 shares of company stock, reducing his personal holding by 4.65 percent. The disposal was disclosed in a Securities and Exchange Commission filing and represents the largest insider sale since director Jonathan Rothberg’s multi-day divestitures earlier this month. While Doherty reiterated a focus on disciplined financial management and sustained revenue growth, the cluster of recent insider exits may introduce short-term selling pressure and warrants monitoring by institutional investors, who currently hold approximately 38 percent of outstanding shares.